Systemic Vasculitis (Polyarteritis Nodosa)

Comprehensive Clinical Guide: Polyarteritis Nodosa (PAN)

Polyarteritis Nodosa (PAN) is a systemic necrotizing vasculitis that primarily affects medium-sized muscular arteries. Unlike many other vasculitides, PAN characteristically spares the pulmonary circulation and typically does not involve the small vessels (arterioles, capillaries, or venules), which helps distinguish it from ANCA-associated vasculitides. This guide serves as a clinical reference for the diagnosis, management, and long-term monitoring of this complex multi-system disease.

1. Clinical Definition and Etiology

Definition

Polyarteritis Nodosa is a rare, life-threatening autoimmune condition characterized by segmental, necrotizing inflammation of medium-sized arteries. The inflammation leads to the formation of microaneurysms, arterial occlusions, and subsequent tissue ischemia or infarction in the organs supplied by the affected vessels.

Etiology and Pathogenesis

The exact trigger for PAN remains idiopathic in the majority of cases. However, several associations have been established:
* Viral Triggers: A significant subset of cases (approximately 10-30%) is associated with chronic Hepatitis B (HBV) infection. This is believed to be caused by the deposition of HBV-antigen/antibody complexes in the arterial walls.
* Immunological Mechanisms: The pathology is driven by Type III hypersensitivity reactions. Antigen-antibody complexes deposit in the vessel walls, activating the complement system, recruiting neutrophils, and releasing lysosomal enzymes that cause fibrinoid necrosis.
* Genetic Factors: While not strictly hereditary, certain HLA subtypes have been investigated for increased susceptibility to inflammatory vascular responses.

2. Deep-Dive: Pathophysiology and Vascular Mechanics

The hallmark of PAN is "segmental" involvement. This means an artery may show areas of acute, severe inflammation interspersed with segments of entirely normal vessel wall.

The Mechanism of Lesion Formation

1. Endothelial Injury: Immune complex deposition triggers a cascade of inflammatory mediators (IL-1, TNF-alpha).
2. Transmural Necrosis: Inflammation extends through the entire thickness of the arterial wall, weakening the tunica media.
3. Microaneurysm Formation: The loss of structural integrity leads to localized dilation (microaneurysms), which are pathognomonic for PAN and frequently found in the renal, hepatic, and mesenteric arteries.
4. Thrombosis and Ischemia: The internal elastic lamina is destroyed, leading to intimal proliferation and thrombosis. The resulting downstream ischemia causes the clinical symptoms associated with organ failure.

Organ-Specific Impacts

3. Clinical Indications and Diagnostic Roadmap

Clinical Staging and Grading

The Five-Factor Score (FFS) is the standard clinical tool used to predict mortality in PAN patients. A score of 1 or higher is associated with a significantly poorer prognosis.

Diagnostic Criteria (ACR 1990)

A patient is classified as having PAN if they meet at least 3 of the following 10 criteria:
1. Weight loss ≥ 4 kg.
2. Livedo reticularis (mottled skin discoloration).
3. Testicular pain or tenderness.
4. Myalgias, weakness, or leg tenderness.
5. Mono- or polyneuropathy.
6. Diastolic BP > 90 mmHg.
7. Elevated BUN or creatinine.
8. Hepatitis B positivity.
9. Arteriographic abnormalities (aneurysms or occlusions).
10. Biopsy of medium-sized artery showing polymorphonuclear neutrophils.

4. Differential Diagnosis

Distinguishing PAN from other vasculitides is critical, as treatment protocols differ significantly.

• ANCA-Associated Vasculitides (GPA, MPA, EGPA): These involve small vessels and are typically ANCA-positive. PAN is almost always ANCA-negative.
• Systemic Lupus Erythematosus (SLE): Can present with vasculitis, but usually involves serositis, ANA positivity, and complement consumption.
• Infectious Vasculitis: Endocarditis can mimic PAN through embolization.
• Cryoglobulinemic Vasculitis: Often associated with Hepatitis C; usually presents with palpable purpura, unlike the nodules/infarcts of PAN.

5. Risks, Side Effects, and Contraindications

Treatment involves aggressive immunosuppression, which carries significant risks:

• Corticosteroids (Prednisone): Risks include steroid-induced diabetes, osteoporosis, avascular necrosis, and secondary infections.
• Cyclophosphamide: A potent cytotoxic agent. Risks include hemorrhagic cystitis, bladder cancer, infertility, and severe bone marrow suppression.
• Biological Agents (e.g., Rituximab): Risk of infusion reactions and reactivation of latent infections (e.g., Hepatitis B, Tuberculosis).
• Contraindications: Live vaccines should be avoided during active immunosuppressive therapy. Cyclophosphamide must be used with extreme caution in patients with pre-existing bone marrow failure.

6. Massive FAQ Section: Frequently Asked Questions

Q1: Is Polyarteritis Nodosa curable?

A: While "cure" is a strong term in autoimmune medicine, PAN is highly treatable. With early diagnosis and aggressive immunosuppression, many patients achieve long-term remission.

Q2: Why is the lung typically spared in PAN?

A: The pathogenesis of PAN is specific to medium-sized muscular arteries. The pulmonary vasculature consists primarily of small vessels/capillaries, which explains why pulmonary involvement is notably absent in PAN, unlike in GPA or microscopic polyangiitis.

Q3: What is the significance of the "Mononeuritis Multiplex"?

A: It is the clinical hallmark of nerve ischemia. Patients present with sudden, asymmetric sensory and motor deficits (e.g., foot drop) caused by the inflammation of the vasa nervorum (the small arteries supplying the nerves).

Q4: How is Hepatitis B-associated PAN treated differently?

A: Patients with HBV-associated PAN often require a combination of short-term immunosuppression (to control the immediate vasculitis) followed by aggressive antiviral therapy (e.g., entecavir or tenofovir) and potentially plasma exchange.

Q5: Is a biopsy always required?

A: Not always. If angiography reveals characteristic microaneurysms in the renal or mesenteric arteries, this is often considered diagnostic in the appropriate clinical context.

Q6: What is the role of imaging in diagnosis?

A: Digital Subtraction Angiography (DSA) or CT Angiography (CTA) is crucial. The presence of multiple microaneurysms in the visceral arteries is highly specific for PAN.

Q7: Can children get PAN?

A: Yes, there is a distinct pediatric form known as Cutaneous Polyarteritis Nodosa, which is usually more limited to the skin and joints, though systemic forms can occur.

Q8: What are the warning signs of a relapse?

A: Recurrence of constitutional symptoms (fever, weight loss), new onset of skin nodules, or worsening hypertension are early red flags that require immediate clinical evaluation.

Q9: Does PAN cause long-term kidney damage?

A: Yes, if untreated, the renal artery involvement can lead to severe hypertension and chronic kidney disease (CKD). Maintaining blood pressure control is a vital component of long-term management.

Q10: How often should I monitor my condition once in remission?

A: Monitoring typically involves quarterly blood work (CBC, ESR, CRP, Renal Function) and blood pressure checks. Frequency may decrease as the duration of sustained remission increases.

7. Long-Term Prognosis

The prognosis for PAN has improved dramatically over the last several decades.
* Untreated: The 5-year survival rate is historically less than 15%.
* Treated: With modern immunosuppressive protocols (Corticosteroids and Cyclophosphamide), the 5-year survival rate exceeds 80%.

Key Determinants of Prognosis:
1. Early Intervention: Damage to organs like the kidneys or intestines is often irreversible.
2. Complications of Therapy: Infections are the leading cause of morbidity in treated patients.
3. Relapse Rate: Relapse occurs in approximately 20-30% of patients, necessitating long-term maintenance therapy with agents like Azathioprine or Mycophenolate Mofetil.

Clinical Summary Table

Disclaimer: This guide is intended for educational and clinical reference purposes only. It does not replace the judgment of a qualified rheumatologist or internist. Always consult current clinical guidelines (EULAR/ACR) for specific patient management.